Clinical Trial Update: First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1]

View source ↗

Summary

Phase 1 first-in-human trial of GSK3368715 in solid tumors and diffuse large B-cell lymphoma has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Neoplasms

Drugs mentioned

• GSK3368715

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2022-05-20